UNIHEALTH

Unihealth Hospitals Limited

Listed company · ISIN INE0PRF01011 · NSE SM · FV ₹10
Last price
₹581
-3.21%today
What this company does

Unihealth Hospitals Limited is a listed company. It booked ₹65 cr of revenue in its latest half year (H2 FY26) and kept 16.4% of sales as profit.

58out of 100
Equitytale Health Score
Mixed

Healthier than 58% of listed companies we score, on the 5 of 6 measures we could read for it. Each measure is ranked against the 2,335–2,886 companies that reported it.

Measures financial condition, not whether to buy. Learn what this score means · How this is calculated

Price momentum
oversold
RSI (14)
27

At close. Not part of the score.

Profitability & returns65

How much profit it earns on the money it employs

Balance sheet75

How much it owes, and whether earnings cover the interest

Cash quality32

Whether reported profit actually arrives as cash

Valuation20

What today's price implies, against our models or its peers

Governance & risk100

How much of the promoters' stake is pledged, and how much they hold · highest in its sector on what we could measure

Not measurable for this company: growth & consistency. Those pillars are left out of the score rather than counted as zero.

Is this company doing well?
not investment advice
Looks broadly healthy
Strengths
✓ Makes a profit
✓ Strong 16% net margin
✓ Promoters hold 65%
✓ No promoter shares pledged
✓ Strong 16% return on equity
Watch-outs
None flagged from our data

What if I invest in UNIHEALTH?

Set a growth rate and see what a monthly SIP would add up to. Your assumption, our arithmetic.

You would put in
₹12.00 lakh
120 instalments
At 10% a year, it would become
₹20.15 lakh

The starting rate is a round number, not a view on this company — this is your assumption, and the figure above is arithmetic on it. Returns are not steady year to year, and a real holding would not grow in a straight line. We do not publish price targets or predict returns.

Key ratios · latest half year + price
₹581▼ -3.21%
latest close · 2026-10-01
52-wk low ₹54052 sessions so far52-wk high ₹820
Is it cheap or expensive?
What you pay for the profits, book value and cash flow. Higher isn't automatically worse — it can signal faster growth.
P/E ratio42.0High
LowAverageHigh
P/B ratio6.63High
Below bookModerateHigh
EV / EBITDA19.1High
LowAverageHigh
How good is the business?
How much profit it earns from its money and its sales.
Return on equity15.6%Strong
WeakFairStrong ▸15%
Return on capital15.9%Strong
WeakFairStrong
Net margin16.4%Strong
ThinDecentStrong
EBITDA margin37.0%Healthy
ThinDecentHealthy
Is it financially safe?
How much it owes, and whether it can comfortably cover it.
Debt to equity0.11Comfortable
LowModerateHigh ▸1
Interest cover15.4×Strong
RiskyOkayStrong ▸5×
Current ratio5.33Ample
Tight ◂1HealthyAmple
More figures
Market cap
₹912 cr
Book value
₹88
EPS
₹6.92
latest half year
Net debt
₹11 cr
owes more than its cash
Enterprise value
₹923 cr
EBITDA
₹48 cr
annualised
EBIT
₹36 cr
annualised
Operating margin
27.3%
Return on assets
8.4%
Earnings yield
2.38%
P/S
6.98
Sales / share
₹83.2
Tax rate
-2.4%
Face value
₹10
Shares
1.6 cr
Working capital
₹127 cr
Current assets
₹156 cr
Current liabilities
₹29 cr
Delivery %
74.5%
Strong / safeFairWeak / riskyValuation — a level, not good/badBands are general rules of thumb, not advice.

P/E, ROE, ROCE and margins are annualised from the latest half year; per-share and balance-sheet ratios use the most recent balance sheet on file · prices as of 2026-10-01.

Worth vs price · from the exchange filings
not investment advice
Hard to value confidentlyLow confidence
Too few reliable models — the filings don't support two independent estimates of value.
Models span ₹129–₹129, midpoint ₹129

An educational model from the company's own filings, every assumption shown — not investment advice or a price target. Prices can stay above or below any model for years.

P&L · H2 FY26 (consolidated)
Revenue from Operations₹65 cr
Other Income₹2 cr
Total Income₹67 cr
Cost of Materials₹1 cr
Purchases of Stock-in-Trade₹14 cr
Inventory Change (±)₹-3 cr
Employee Benefit Expense₹10 cr
Finance Costs₹1 cr
Depreciation & Amortisation₹6 cr
Other Expenses₹20 cr
Total Expenses₹51 cr
Profit before Tax₹17 cr
Tax Expense₹-39.8 L
Share of JV / Associates₹-1.1 L
Net Profit₹17 cr
Net margin on total income25.3%
Where the money goes · H2 FY26
% of total income
Materials + stock-in-trade₹13 cr18.7%
Employee benefit expense₹10 cr15.3%
Finance costs₹1 cr1.7%
Depreciation & amortisation₹6 cr9.3%
Other expenses₹20 cr29.7%
Profit for the period₹17 cr25.2%
Total income ₹67 cradds up to ₹100 ✓
Balance sheet & cash flow · as of Mar 2026
Low debt
Total assets
₹254 cr
Shareholder equity
₹138 cr
parent shareholders
Total debt
₹21 cr
Cash
₹10 cr
Who owns it · 2026-09-15
No pledge
Promoter
64.8%
FII / Foreign
0.0%
DII / Domestic
0.5%
Retail / others
34.7%
Promoter stake down 4.0% over the last 5 quarters.
Who controls this company, and what it pays them

Most Indian companies are controlled by a family or group — the promoters. The exchange requires them to be listed by name, including members who own no shares at all, and requires the company to disclose any business it does with them.

The promoter group — 6 named members
owning 64.8% between them · as of 2026-09-15
ANURAG RATAN KUMAR SHAH30.61%
AKSHAY MAHENDRA PARMAR25.83%
PRAFULLA MAHENDRA PARMAR4.78%
SHANTILAL BHIKCHAND KATARIA2.22%
SANGEETA SHAH0.80%
MAYURI AKSHAY PARMAR0.56%

Names and holdings from the company’s shareholding pattern filed with the exchange; transactions from the related-party note in its annual report. Every figure is as filed — these are legal, disclosed dealings, and what to make of them is your call.

Money it raised, and what it did with it

When a company raises money from investors, it has to say up front what the money is for. The rules then make it report, every three months until the money is gone, how much of each of those things it has actually paid for — so a promise made while asking for the money can be checked afterwards.

₹10.6 L raised in May 2025 by selling shares to selected investors

As of Mar 2026, the company says it has spent 44% of what it set aside.

Funding to its Subsidiary , UMC Hospitals Private Limited to support Capital Expenditures (CAPEX) and working capital requirement for the hospital in India.
55%
of what was set aside
General Corporate Purpose, which includes, without limitation, strategic initiatives, funding growth opportunities, strengthening marketing capabilities and brand building exercises, meeting ongoing general corporate contingencies, fund raising expense and other expenses incurred in ordinary course of business
0%
of what was set aside

The rupee amounts in this company’s own breakdown don’t add up to the amount it says it raised — a common filing slip, where a table meant to be read in lakhs is entered as whole rupees. Rather than guess which is right, we show only the percentages, which are unaffected.

₹56.5 L raised in Sep 2023 by selling shares to the public

As of Mar 2026, the company says it has spent 78% of what it set aside.

Investment in our joint venture, Victoria Hospital Limited (VHL), Kampala, Uganda for funding its capital expenditure requirements for proposed expansion and working capital requirements of VHL
now filed as: No Modification
100%
of what was set aside
Investment in our joint venture, UMC Global Health Limited (UMCGHL), Nigeria for funding its capital expenditure requirements for proposed expansion
now filed as: No Modification
63%
of what was set aside
Investment in our subsidiary, Biohealth Limited (BL), Tanzania for funding its capital expenditure requirements for proposed expansion
now filed as: No Modification
15%
of what was set aside
NA
now filed as: Investment in our subsidiaries namely UMC Hospitals Private Limited (India) and in Unihealth Holdings Limited (Mauritius) to support expansion and acquisition of projects across India and Africa
budget changed
100%
of what was set aside
General Corporate Purpose
now filed as: No Modification
100%
of what was set aside
Issue Expenses
now filed as: No Modification
100%
of what was set aside

The rupee amounts in this company’s own breakdown don’t add up to the amount it says it raised — a common filing slip, where a table meant to be read in lakhs is entered as whole rupees. Rather than guess which is right, we show only the percentages, which are unaffected.

Every figure above is taken from the statement the company files with the stock exchange each quarter, for as long as money it has raised remains unspent. The only thing we work out is how much of each stated purpose has been paid for — one number divided by another from the same filing. Whether a plan that changed was a good change is not something a filing can tell you. See the filing

How the stock has moved · adjusted for splits & bonuses
Data from primary exchange filings · analysis tool, not investment advice.